Literature DB >> 1847900

Kinetic abnormalities of the red blood cell sodium-proton exchange in hypertensive patients.

M Canessa1, K Morgan, R Goldszer, T J Moore, A Spalvins.   

Abstract

The present study was designed to examine the kinetics of Na(+)-H+ exchange in red blood cells of normotensive and hypertensive subjects and its relation to the previously reported abnormalities in Na(+)-Li+ exchange. The Na(+)-H+ antiporter activation kinetics were studied by varying cell pH and measuring net Na+ influx (mmol/l cell x hr = units) driven by an outward H+ gradient. The Na(+)-Li+ exchange was determined at pH 7.4 as sodium-stimulated Li+ efflux. Untreated hypertensive patients (n = 30) had a higher maximal rate of Na(+)-Li+ exchange (0.43 +/- 0.05 versus 0.26 +/- 0.02 units, p less than 0.0003), a higher maximal rate of Na(+)-H+ exchange (62.3 +/- 6.2 versus 47 +/- 4 units; p less than 0.02), but a similar affinity for cell pH compared with normotensive subjects (n = 46). The cell pH activation of the Na(+)-H+ antiporter exhibited a lower Hill coefficient than that of normotensive subjects (1.61 +/- 0.12 versus 2.56 +/- 0.14; p less than 0.0001). This index of occupancy of internal H+ regulatory sites was found reduced in most of the hypertensive patients (73%) whether their hypertension was untreated or treated. Hypertensive patients with Na(+)-Li+ exchange above 0.35 units (0.68 +/- 0.057 units, n = 16) did not exhibit elevated maximal rates of Na(+)-H+ exchange (57.3 +/- 10 units, NS) in comparison with those with Na(+)-Li+ exchange below 0.35 units (66.4 +/- 7.6 units, n = 26), but both groups exhibited reduced Hill coefficients. Hypertensive patients with enhanced Na(+)-H+ exchange activity (more than 90 units) had normal maximal rates of Na(+)-Li+ exchange.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847900     DOI: 10.1161/01.hyp.17.3.340

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Abnormal Na+/H+ antiport activity in cultured fibroblasts from NIDDM patients with hypertension and microalbuminuria.

Authors:  R Trevisan; M R Cipollina; E Duner; M Trevisan; R Nosadini
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

2.  The relationship of urinary albumin excretion rate to ambulatory blood pressure and erythrocyte sodium-lithium countertransport in NIDDM.

Authors:  J H Pinkney; W J Foyle; A E Denver; V Mohamed-Ali; S McKinlay; J S Yudkin
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

3.  Abnormal Na+/H+ antiporter phenotype and turnover of immortalized lymphoblasts from type 1 diabetic patients with nephropathy.

Authors:  L L Ng; J E Davies; M Siczkowski; F P Sweeney; P A Quinn; B Krolewski; A S Krolewski
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 4.  Potassium in hypertension.

Authors:  Maria Carolina Delgado
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

5.  Hypertensive sodium-proton exchanger phenotype persists in immortalized lymphoblasts from essential hypertensive patients. A cell culture model for human hypertension.

Authors:  D Rosskopf; E Frömter; W Siffert
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  Platelet Na+/H+ antiport activity in patients with insulin-dependent diabetes mellitus with and without diabetic nephropathy.

Authors:  R Düsing; M Sorger; L Mattes; B O Göbel; G Hoffmann; D Rosskopf; H Vetter; W Siffert
Journal:  Clin Investig       Date:  1993-02

7.  Expression of the human sodium/proton exchanger NHE-1 in Xenopus laevis oocytes enhances sodium/proton exchange activity and establishes sodium/lithium countertransport.

Authors:  S Busch; B C Burckhardt; W Siffert
Journal:  Pflugers Arch       Date:  1995-04       Impact factor: 3.657

8.  Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension.

Authors:  W Siffert; D Rosskopf; A Moritz; T Wieland; S Kaldenberg-Stasch; N Kettler; K Hartung; S Beckmann; K H Jakobs
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.